Rigel

South San Francisco, US · 1 known investors

Rigel is a biopharmaceutical company that develops and markets therapies including olutasidenib, pralsetinib, and fostamatinib for conditions such as acute myeloid leukemia and chronic immune thrombocytopenia. This page invites investigator-sponsored research proposals, offering study drug and/or monetary grants for independent studies aligned with Rigel's therapeutic areas.